Spakem10 mg

Spakem 10 mg is a centrally acting skeletal muscle relaxant primarily prescribed to relieve spasticity (involuntary muscle stiffness, tightness, and spasms) arising from disorders of the central nervous system. It is indicated for the following conditions:

• Spasticity resulting from multiple sclerosis
• Flexor spasms with associated pain, clonus, and muscular rigidity
• Skeletal muscle spasm caused by rheumatic disorders
• Spasticity due to spinal cord injuries and other spinal cord diseases
• Muscle spasticity following cerebrovascular accidents (stroke), or resulting from neoplastic or degenerative brain disease

By reducing excessive muscle tone, Spakem 10 mg helps improve mobility, eases pain associated with muscle spasms, and supports rehabilitation in patients with chronic neuromuscular conditions. It treats the symptom of spasticity rather than curing the underlying neurological disease.

Centrally acting Skeletal Muscle Relaxants

Spakem 10 mg is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It exerts its muscle-relaxant effect mainly at the spinal cord level by selectively stimulating GABA_B receptors.

Mechanism of Action

Activation of GABA_B receptors by Spakem 10 mg inhibits the release of the excitatory neurotransmitters glutamate and aspartate from nerve terminals. This suppresses both monosynaptic and polysynaptic reflexes at the spinal level, reducing the excessive motor neuron activity that causes spasticity. Spakem 10 mg may also act at supraspinal (brain) sites, contributing to central nervous system depression, and it produces a measurable antinociceptive (pain-relieving) effect independent of its muscle-relaxant action.

Pharmacokinetics

• Absorption: Rapidly and largely absorbed from the gastrointestinal tract after oral administration, though absorption can vary between individuals.
• Onset & Peak Effect: Peak plasma concentrations are typically reached within 2 to 3 hours of an oral dose.
• Distribution: Crosses the blood-brain barrier in limited amounts and also crosses the placental barrier.
• Metabolism: A small fraction is metabolised in the liver; most of the dose is excreted unchanged.
• Elimination: Primarily eliminated via the kidneys, with an elimination half-life of approximately 2.5 to 4 hours in patients with normal renal function.

Spakem 10 mg can interact with several classes of medicines and substances, which may alter its effectiveness or increase the risk of adverse effects. Patients should inform their physician of all medicines, supplements, and substances they are using.

• Increased sedation may occur when Spakem 10 mg is taken with other central nervous system depressants, alcohol, or synthetic opioids; the risk of respiratory depression is also increased in such combinations.
• Combined use with antihypertensive medicines is likely to increase the fall in blood pressure, so the antihypertensive dosage may need adjustment.
• Concomitant use with tricyclic antidepressants may potentiate Spakem 10 mg's effects, resulting in pronounced muscular hypotonia (excessive muscle relaxation).
• In patients with Parkinson's disease taking levodopa and carbidopa together with Spakem 10 mg, there have been reports of mental confusion, hallucinations, headache, nausea, and agitation.
• Concurrent use with monoamine oxidase (MAO) inhibitors may increase central nervous system depressant effects; dosage adjustment of one or both agents may be required.
• Caution is needed when Spakem 10 mg is given with magnesium sulphate or other neuromuscular blocking agents, as a synergistic muscle-relaxant effect may theoretically occur.

Like all medicines, Spakem 10 mg can cause side effects, although not everyone experiences them. The most commonly reported adverse reactions are transient drowsiness, daytime sedation, dizziness, weakness, and fatigue, which often diminish as the body adjusts to treatment or following dose adjustment.

Central Nervous System

Headache and insomnia occur in fewer than 10% of patients. Less commonly reported effects include euphoria, excitement, depression, confusion, hallucinations, paraesthesia (tingling sensations), nightmares, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, and respiratory depression.

Cardiovascular

Hypotension occurs in fewer than 10% of patients. Rare effects include shortness of breath (dyspnoea), palpitations, chest pain, and fainting (syncope).

Gastrointestinal

Nausea occurs in approximately 10% of patients, and constipation in fewer than 10%. Rare gastrointestinal effects include dry mouth, loss of appetite, taste disturbance, abdominal pain, vomiting, diarrhoea, and a positive test for occult blood in stool.

Genitourinary

Urinary frequency occurs in fewer than 10% of patients. Rare effects include bedwetting (enuresis), urinary retention, painful urination (dysuria), impotence, inability to ejaculate, increased night-time urination (nocturia), and blood in urine (haematuria).

Other Effects

Other reported effects include skin rash, itching (pruritus), ankle swelling, excessive sweating, weight gain, nasal congestion, visual disturbances, liver function disorders, and a paradoxical increase in spasticity. Excessive muscle relaxation (hypotonia) sufficient to interfere with walking or movement may occur but usually improves with dose readjustment, typically by reducing the daytime dose and increasing the evening dose.

Spakem 10 mg is classified as Pregnancy Category B3. The safety of Spakem 10 mg use during pregnancy has not been firmly established, and it is known to cross the placental barrier. It should only be given to pregnant women if, in the judgement of the treating physician, the potential benefit to the mother outweighs the possible risk to the foetus.

Spakem 10 mg is excreted in breast milk; however, available evidence suggests that the amounts transferred are small and are not expected to cause adverse effects in breastfed infants. Breastfeeding mothers should still use Spakem 10 mg only under medical supervision.

• Lower doses (approximately 5 mg per day) are recommended for patients with impaired renal function or those undergoing chronic haemodialysis.
• Patients with psychotic disorders, schizophrenia, depressive or manic disorders, or confusional states should be treated cautiously and monitored closely, as Spakem 10 mg may exacerbate these conditions.
• In patients with epilepsy and muscle spasticity, Spakem 10 mg may be used under appropriate supervision provided adequate anticonvulsant therapy is continued; the seizure threshold may be lowered, and seizures have been reported after abrupt cessation of treatment or overdose.
• Use with caution in patients with a history of peptic ulcer disease, cerebrovascular disease, or hepatic, renal, or respiratory failure.
• Careful monitoring of respiratory and cardiovascular function is essential, particularly in patients with cardiopulmonary disease or respiratory muscle weakness.
• Spakem 10 mg may improve neurogenic bladder-emptying disturbances; however, in patients with pre-existing sphincter hypertonia, acute urinary retention may occur, so caution is advised.
• Spakem 10 mg has not shown significant benefit in stroke patients, who have also demonstrated poor tolerance to the medicine.
• Periodic laboratory monitoring is advised in patients with hepatic disease or diabetes mellitus to detect any medicine-induced changes in these underlying conditions.
• Avoid abrupt discontinuation of Spakem 10 mg; the dose should be tapered gradually to prevent withdrawal symptoms such as rebound spasticity, hallucinations, agitation, or seizures.

Symptoms of Spakem 10 mg overdose may include profound muscle weakness (hypotonia), excessive drowsiness, vomiting, salivation, respiratory depression, seizures, and, in severe cases, coma. Cardiovascular effects such as hypotension or bradycardia may also be observed.

Gastric lavage is important in cases of severe overdose. Management is primarily supportive, focusing on maintaining adequate respiratory function and cardiovascular stability; mechanically assisted ventilation may be required in severe cases. There is no specific antidote for Spakem 10 mg overdose, and any suspected overdose should be treated as a medical emergency requiring immediate hospital attention.

Store Spakem 10 mg below 30°C, away from direct light and moisture. Keep the medicine out of the reach and sight of children.

Centrally acting Skeletal Muscle Relaxants

Spakem 10 mg inhibits both monosynaptic and polysynaptic reflexes at the spinal level by stimulating the GABAB receptors, which in turn inhibits the release of glutamate and aspartate. Additionally, it may act at intraspinal sites, leading to CNS depression. Spakem 10 mg also demonstrates an antinociceptive effect.